Marina Bacac

Schlieren, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 69 publications

Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control.

Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control.

Journal: Cancer research communications

Published: March 18, 2026

CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB.

CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB.

Journal: Antibodies (Basel, Switzerland)

Published: September 27, 2025

Publisher Correction: Feasibility of multiomics tumor profiling for guiding treatment of melanoma.

Publisher Correction: Feasibility of multiomics tumor profiling for guiding treatment of melanoma.

Journal: Nature medicine

Published: August 01, 2025

Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.

Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.

Journal: Nature communications

Published: May 21, 2025

Molecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell Lymphoma.

Molecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell Lymphoma.

Journal: Blood advances

Published: April 21, 2025

Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma.

Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma.

Journal: Blood advances

Published: April 21, 2025

A tumor profiling resource for ovarian cancer: insights into chemotherapy-driven heterogeneity and personalized treatment strategy.

A tumor profiling resource for ovarian cancer: insights into chemotherapy-driven heterogeneity and personalized treatment strategy.

Journal: Nature communications

Published: March 09, 2025

Mechanistic insights into resistance mechanisms to T cell engagers.

Mechanistic insights into resistance mechanisms to T cell engagers.

Journal: Frontiers in immunology

Published: February 25, 2025

Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.

Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.

Journal: Blood

Published: February 20, 2025

Resolving the structural basis of therapeutic antibody function in cancer immunotherapy with RESI.

Resolving the structural basis of therapeutic antibody function in cancer immunotherapy with RESI.

Journal: Nature communications

Published: December 13, 2024

Feasibility of multiomics tumor profiling for guiding treatment of melanoma.

Feasibility of multiomics tumor profiling for guiding treatment of melanoma.

Journal: Nature medicine

Published: July 09, 2024

Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia.

Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia.

Journal: Nature communications

Published: March 08, 2024

Showing 1-12 of 69

Last Updated: 09/26/2026